Gagnon Robert E.
Chief Financial Officer
Gagnon Robert E. has filed 8 SEC Form 4 filings (8 transaction rows) across 3 companies, including IRD, HBIO, VSTM, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.
On the most recent filing, Gagnon Robert E. is listed as Chief Financial Officer at Opus Genetics, Inc. Inside the rolling window, Gagnon Robert E. reported no open-market purchases and 5 open-market sales totaling $196K in IRD and VSTM. The largest disclosed transaction in the window is a sale of 28,000 IRD shares on Sep 3, 2026, worth $127K.
Companies traded
Other insiders at IRD
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$196K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Gagnon Robert E. made?
Gagnon Robert E. has filed 8 SEC Form 4 filings (8 transaction rows) across 3 companies, including IRD, HBIO, VSTM since 2025.
Which companies does Gagnon Robert E. trade?
Gagnon Robert E. has filed SEC Form 4 disclosures for 3 companies, including IRD, HBIO, VSTM.
When was Gagnon Robert E.'s most recent SEC Form 4 filing?
Gagnon Robert E.'s most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.
What is Gagnon Robert E.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Gagnon Robert E. is listed as Chief Financial Officer.
What is Gagnon Robert E.'s total buy and sell value in the current window?
Inside the rolling retention window, Gagnon Robert E. bought $0 and sold $196K based on SEC Form 4 filings.
What was Gagnon Robert E.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 28,000 IRD shares on 2026-09-03, worth $127K, per SEC Form 4 filings.